[RESEARCH BLOG] · 2026-07-22
Bionano Genomics (BNGO) – **SELL** Signal Amid Recovery‑Phase Market Regime and Weak Fundamentals
By Pierre Brunelle · Founder & Research Lead
Lede: Bionano Genomics closed the U.S. session on 2026‑07‑21 at $1.12, down 0.88 % from the prior close. The LOPJLB proprietary scanner now flags a SELL directional signal with a –5 score while the broader market sits in a RECOVERY regime.
Recent Catalysts
- Bionano Announces Hiring of Chief Scientific Officer – 2026‑06‑24
- Bionano Announces 67% Year‑Over‑Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption – 2026‑06‑18
- Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders – 2026‑06‑11
These releases collectively illustrate scientific momentum—new leadership, expanding adoption at the European Society of Human Genetics (ESHG), and peer‑reviewed evidence of OGM utility in reproductive health—but they arrive against a backdrop of deteriorating profitability and a market‑cap of only $12.9 M, reinforcing the current sell‑side bias.
Fundamentals and Valuation
BNGO’s valuation metrics remain deeply distressed.
| Metric | Value |
|---|---|
| P/E (TTM) | ‑0.19 |
| EV/EBITDA | ‑0.74 |
| Price‑to‑Book | 0.16 |
| Debt/Equity | 45.42 |
| Interest Coverage | ‑114.6 |
| Gross Margin | 46.97 % |
| Operating Margin | ‑114.0 % |
| Net Margin | ‑109.9 % |
| ROIC | ‑42.83 % |
| Analyst Target Price | $46.50 |
| Analyst Recommendation | Buy |
Key points:
- Profitability – All return metrics are negative (ROIC ‑42.83 %, ROE ‑73.78 %, ROA ‑48.76 %).
- Margins – Gross margin is respectable at 46.97 %, but operating and net margins are deeply negative, reflecting heavy R&D and SG&A spend.
- Cash Flow – Free‑cash‑flow yield is ‑150.1 %, confirming cash outflows far exceed operating cash generation.
- Revenue – Twelve‑month YoY growth is modest at 3.6 %. Historical revenue peaked at $36.1 M in 2023 before slipping to $28.5 M in 2025 (‑20.9 % from the 2023 high). The 2020‑2025 CAGR is roughly 23 %, but the recent decline signals a slowdown in market penetration.
- Earnings – EPS remains deeply negative, moving from ‑$14,194.8 in 2020 to ‑$4.85 in 2025.
- Valuation Gap – The current price of $1.12 reflects a 96 % discount to the analyst target, a gap that would require a dramatic turnaround in revenue, margin expansion, and debt reduction.
Revenue and Margin Evolution (2020‑2025)
- Gross margin improved from 32.61 % (2020) to 46.97 % (2025).
- Operating margin deteriorated from ‑453.4 % (2020) to ‑117.0 % (2025).
- Net margin moved from ‑483.4 % (2020) to ‑92.59 % (2025).
- Free‑cash‑flow fell from ‑$126.9 M (2023) to ‑$16.3 M (2025); although the absolute burn has lessened, cash outflow relative to revenue remains alarming.
ETF Ownership
BNGO’s institutional footprint is thin but concentrated. The stock is held by a single exchange‑traded fund, TYNE, which accounts for 5.37 % of outstanding shares and ranks fourth among the fund’s holdings. This modest concentration can amplify price movements when the ETF rebalances, but broader market sentiment from large‑cap or sector‑focused funds is unlikely to provide a stabilizing influence.
LOPJLB Signal Read
The LOPJLB engine currently issues a SELL directional signal for BNGO, with a composite score of ‑5. The market regime is classified as RECOVERY, a phase that typically favors stocks with solid balance sheets and positive cash flow—attributes that BNGO lacks.
- Composite performance (PERF): ‑7.20
- Quality fund score: 0.00 (no measurable strength)
- Growth score: 35.00 (reflects modest revenue uptick)
- Archetype: Balanced (mix of growth potential and value concerns)
Underlying component scores:
- Value = 0.00
- Growth = 35.00
- GARP = 9.60
- Quality = ‑8.70
Readers are encouraged to explore the interactive chart on the BNGO page for a visual overlay of the signal components, and to review the full methodology for insight into how the directional and regime scores are derived.
Next Steps & Resources
- BNGO on LOPJLB – detailed stock profile
- BNGO Earnings transcripts and filings
- LOPJLB Screener – broader market screening tool
The information provided herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consult professional advisors before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.